Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

References

• Balfour H. Cytomegalovirus: the troll of transplantation. Arch Intern Med. 1979;139(3):279–280.
   PubMedGoogle Scholar
• Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;17:664–673.
   PubMed Web of Science ®Google Scholar
• Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program. 2011;2011:305–309.
   PubMed Web of Science ®Google Scholar
• Buyck HCE, Griffiths PD, Emery VC. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J Clin Virol. 2010;49(1):32–36.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol. 2010;91(5):877–885.
   PubMed Web of Science ®Google Scholar
• Hambach L, Stadler M, Dammann E, et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29(11):903–906.
   PubMed Web of Science ®Google Scholar
• Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood. 2010;115(25):5147–5153.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Zelini P, et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One. 2012;7(7):e41648.
   PubMed Web of Science ®Google Scholar
• Ciáurriz M, Zabalza A, Beloki L, et al. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Cell Mol Life Sci. 2015;72(21):4049–4062.
   PubMed Web of Science ®Google Scholar
• Cohen L, Yeshurun M, Shpilberg O, et al. Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2015;17(4):510–517.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Martino R, Barba P, et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant. 2010;45(3):534–542.
   PubMed Web of Science ®Google Scholar
• Guerrero A, Riddell SR, Storek J, et al. Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant. 2012;18(1):66–75.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu LP, Liu KY, et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol. 2016;75:10–15.
   PubMed Web of Science ®Google Scholar
• Emery V, Zuckerman M, Jackson G, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162:25–39.
   PubMed Web of Science ®Google Scholar
• Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol. 2012;156:559–572.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis. 2014;27(6):554–559.
   PubMed Web of Science ®Google Scholar
• Sellar RS, Peggs KS. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update. Expert Opin Biol Ther. 2014;14(8):1121–1126.
   PubMed Web of Science ®Google Scholar
• Rooney C, Leen A. Moving successful virus-specific t-cell therapy for hematopoietic stem cell recipients to late phase clinical trials. Mol Ther Nucleic Acids. 2012;1:e55.
   PubMedGoogle Scholar
• Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine. 2013;31 Suppl 2:B197–B203.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227–240.
   PubMed Web of Science ®Google Scholar
• Venton G, Crocchiolo R, Fürst S, et al. Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect. 2014;20(2):160–166.
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee MH, Kim SY, et al. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2010;91:886–891.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SO, Choi SH, et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother. 2012;67(6):1486–1492.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61(1):31–39.
   PubMed Web of Science ®Google Scholar
• Gracia-Ahufinger I, Gutiérrez-Aroca J, Cordero E, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation. 2013;95(8):1015–1020.
   PubMed Web of Science ®Google Scholar
• Stuehler C, Stüssi G, Halter J, et al. Combination therapy for multidrug-resistant cytomegalovirus disease. Transpl Infect Dis. 2015;17(5):751–755.
   PubMed Web of Science ®Google Scholar
• Posadas Salas MA, Taber DJ, Chua E, et al. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013;15(6):551–558.
   PubMed Web of Science ®Google Scholar
• Winter M, Guhr K, Berg G. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604–612.
   PubMed Web of Science ®Google Scholar
• Chawla JS, Ghobadi A, Mosley J 3rd, et al. Oral Valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012;14(3):259–267.
   PubMed Web of Science ®Google Scholar
• Barkam C, Kamal H, Dammann E, et al. Improving safety of pre-emptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Bone Marrow Res. 2012;2012:ID874601.
   Google Scholar
• Ruiz-Camps I, Len O, de la Cámara R, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Antivir Ther. 2011;16(7):951–957.
   PubMed Web of Science ®Google Scholar
• Kaynar L, Metan G, Gökahmetoğlu S, et al. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation? J Chemother. 2013;25(5):286–291.
   PubMed Web of Science ®Google Scholar
• Takahata M, Hashino S, Nishio M, et al. Occurrence of adverse events caused by valganciclovir as preemptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis. 2015;17(6):810–815.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Boyd A, Slipper J, et al. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther. 2012;10(11):1249–1264.
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Katagiri T, Ohata K, et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14(1):33–39.
   PubMed Web of Science ®Google Scholar
• Asakura M, Ikegame K, Yoshihara S, et al. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol. 2010;92(2):351–359.
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–1164.
   PubMed Web of Science ®Google Scholar
• Gregg K, Hakki M, Kaul DR. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease. Transpl Infect Dis. 2014;16(2):320–323.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the European Group for blood and marrow transplantation. Blood. 2001;97(2):388–392.
   PubMed Web of Science ®Google Scholar
• Caruso Brown AE, Cohen MN, Tong S, et al. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2015;59(7):3718–3725.
   PubMed Web of Science ®Google Scholar
• Lugthart G, Oomen MA, Jol-van der Zijde CM, et al. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant. 2015;21(2):293–299.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kang JH, Lee JW, et al. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem celltransplant recipients with cidofovir: a single-center experience. Transpl Infect Dis. 2013;15(6):569–574.
   PubMed Web of Science ®Google Scholar
• Rascon J, Verkauskas G, Pasauliene R, et al. Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children afterhematopoietic stem cell transplantation. Pediatr Transplant. 2015;19(4):E111–E114.
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R. Cidofovir activity against poxvirus infections. Viruses. 2010;2(12):2803–2830.
   PubMed Web of Science ®Google Scholar
• Gohring K, Hamprecht K, Jahn G. Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients. Comput Struct Biotechnol J. 2015;13:153–159.
   PubMed Web of Science ®Google Scholar
• Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis. 2011;24(6):605–611.
   PubMed Web of Science ®Google Scholar
• Komatsu TE, Pikis A, Naeger LK, et al. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 2014;101:12–25.
   PubMed Web of Science ®Google Scholar
• Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol. 2013;51(11):3700–3710.
   PubMed Web of Science ®Google Scholar
• Göhring K, Wolf D, Bethge W, et al. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J Clin Virol. 2013;57(1):43–49.
   PubMed Web of Science ®Google Scholar
• Schnepf N, Dhédin N, Mercier-Delarue S, et al. Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient. J Clin Virol. 2013;58(4):733–736.
   PubMed Web of Science ®Google Scholar
• Hanson KE, Swaminathan S. Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management. Future Microbiol. 2015;10:1545–1554.
   PubMed Web of Science ®Google Scholar
• Lu CH, Tsai JH, Wu MZ, et al. Can leflunomide play a role in cytomegalovirus. disease prophylaxis besides its antirheumatic effects? Antivir Ther. 2015;20(1):93–96.
   PubMed Web of Science ®Google Scholar
• Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–426.
   PubMed Web of Science ®Google Scholar
• Chacko B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis. 2012;14(2):111–120.
   PubMed Web of Science ®Google Scholar
• Roy S, He R, Kapoor A, et al. Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation. Antimicrob Agents Chemother. 2015;59(7):3870–3879.
   PubMed Web of Science ®Google Scholar
• Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res. 2011;90:183–186.
   PubMed Web of Science ®Google Scholar
• Germi R, Mariette C, Alain S, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 2014;101:57–61.
   PubMed Web of Science ®Google Scholar
• Arav-Boger R, He R, Chiou CJ, et al. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One. 2010;5(4):e10370.
   PubMed Web of Science ®Google Scholar
• Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs. 2013;31(1):230–246.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young J-AH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–5410.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann A, Stoelben S, et al., for the AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–1789.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al., for the CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic cell transplantation. N Engl J Med. 2013;369(13):1227–1236.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolau GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplant: a phase 3, double blind, placebo controlled, randomized trial. Lancet Infect Dis. 2011;11(4):284–292.
   PubMed Web of Science ®Google Scholar
• Marty FM, Boeckh M. Maribavir and human cytomegalovirus- what happened in the clinical trial and why might the drug have failed? Curr Opin Virol. 2011;1(6):555–562.
   PubMed Web of Science ®Google Scholar
• Griffiths PD. Of London buses and the treatment of cytomegalovirus infection. Rev Med Virol. 2014;24:221–222.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Salibab F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12:3021–3030.
   PubMed Web of Science ®Google Scholar
• Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc. 2013;45:1603–1607.
   PubMed Web of Science ®Google Scholar
• Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis. 2013;13:330.
   PubMed Web of Science ®Google Scholar
• Webel R, Hakki M, Prichard MN, et al. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol. 2014;88(9):4776–4778.
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.
   PubMed Web of Science ®Google Scholar
• Chou S, Ercolani RJ, Marousek G, et al. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemoter. 2013;57(7):3375–3379.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Emery VC. Taming the transplantation troll by targeting terminase. N Engl J Med. 2014;370(19):1844–1846.
   PubMed Web of Science ®Google Scholar
• Borst EM, Kleine-Albers J, Gabaev I, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013;87(3):1720–1732.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–10893.
   PubMed Web of Science ®Google Scholar
• Pilorgé L, Burrel S, Aït-Arkoub Z, et al. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. Antiviral Res. 2014;111:8–12.
   PubMed Web of Science ®Google Scholar
• Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015;5(8):269–277.
   Google Scholar
• Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–1084.
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014;27(1):77–86.
   PubMed Web of Science ®Google Scholar
• Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res. 2015;116:48–50.
   PubMed Web of Science ®Google Scholar
• Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588–6593.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613.
   PubMed Web of Science ®Google Scholar
• Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56:2726–2734.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis. 2010;202:1492–1499.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18(5):731–738.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Lee YJ, Young JW, et al. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation. Am J Kidney Dis. 2015;65(5):780–784.
   PubMed Web of Science ®Google Scholar
• Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev. 2014;258(1):12–29.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Fornara C, et al. Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2009;199(6):829–836.
   PubMed Web of Science ®Google Scholar
• Federmann B, Hägele M, Pfeiffer M, et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia. 2011;25(1):121–129.
   PubMed Web of Science ®Google Scholar
• Bader P, Soerensen J, Jarisch A, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res. 2011;24(3):331–337.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32(2):268–280.
   PubMed Web of Science ®Google Scholar
• Azevedo RI, Soares MV, Albuquerque AV, et al. Long-term immune reconstitution of naive and memory T cell pools after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(5):703–712.
   PubMed Web of Science ®Google Scholar
• Kato R, Tamaki H, Ikegame K, et al. Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2015;94(10):1707–1715.
   PubMed Web of Science ®Google Scholar
• Luo XH, Chang YJ, Huang XJ. Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation. J Immunol Res. 2014;2014:631951.
   PubMed Web of Science ®Google Scholar
• Luo XH, Huang XJ, Li D, et al. Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts. Transpl Infect Dis. 2013;15(1):22–33.
   PubMed Web of Science ®Google Scholar
• Koehne G, Hasa A, Doubrovina E, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant. 2015;21:1663–1678.
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745–3758.
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20:1622–1632.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–4367.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.
   PubMed Web of Science ®Google Scholar
• Casalegno-Garduno R, Schmitt A, Yao J, et al. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunol Immunother. 2010;59:195–202.
   PubMed Web of Science ®Google Scholar
• Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis. 2012;55(8):1064–1073.
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–386.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51(3):591–599.
   PubMed Web of Science ®Google Scholar
• Qasim W, Gilmour K, Zhan H, et al. Interferon-γ capture T cell therapy for persistent adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2013;161:449–452.
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–2656.
   PubMed Web of Science ®Google Scholar
• Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–5123.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700–4702.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Castillo P, Hanley PJ, et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015;23(1):179–183.
   PubMed Web of Science ®Google Scholar
• Hasan AN, Prockop SE, Koehne G, et al. Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous population of HSCT recipients. Blood. 2014;124(21):309.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Gattinoni L, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117:808–814.
   PubMed Web of Science ®Google Scholar
• Jedema I, van de Meent M, Pots J, et al. Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica. 2011;96(8):1204–1212.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Lam S, Shpall EJ, et al. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012;7(63):e362.
   Google Scholar
• Hanley PJ, Cruz CR, Shpall EJ, et al. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy. 2010;12:713–720.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7(285):285.
   Web of Science ®Google Scholar
• Six A, Bellier B, Thomas-Vaslin V, et al. System biology in vaccine design. Microb Biothecnol. 2012;5(2):295–230.
   Google Scholar
• Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine. 2012;30(49):6980–6990.
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256–1263.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290–299.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. Reanalysis of TransVax immunogenicity. Lancet Infect Dis. 2013;13:18.
   PubMed Web of Science ®Google Scholar
• Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444–7447.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Kabanova A, Lanzavecchia A, et al. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol. 2012;32:1324–1331.
   PubMed Web of Science ®Google Scholar
• Giménez E, Blanco-Lobo P, Muñoz-Cobo B, et al. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J Gen Virol. 2015;96(9):2822–2831.
   PubMed Web of Science ®Google Scholar
• Wussow F, Chiuppesi F, Martinez J, et al. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog. 2014;10(11):e1004524.
   PubMed Web of Science ®Google Scholar
• Ciferri C, Chandramouli S, Leitner A, et al. Antigenic characterization of the HCMV gH/gL/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog. 2015;11(10):e1005230.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010;116(10):1655–1662.
   PubMed Web of Science ®Google Scholar
• Borchers S, Luther S, Lips U, et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2011;13(3):222–236.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz RY, Melenhorst J, et al. Naïve T-cell-derived CTL recognize atypical epitopes of CMVpp65 with higher avidity than CMV-seropositive donor-derived CTL – a basis for treatment of post-transplant viral infection by adoptive transfer of T-cells from virus-naïve donors. Cytotherapy. 2013;15(4):S9.
   PubMed Web of Science ®Google Scholar
• Menger L, Gouble A, Marzolini M, et al. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood. 2015;126(26):2781–2789.
   PubMed Web of Science ®Google Scholar
• Zhou X, Dotti G, Krance R, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015;125(26):4103–4113.
   PubMed Web of Science ®Google Scholar